Skip to main content

Table 1 Clinicopathologic factors related to bone metastases in 181 HCC patients

From: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival

  

HCC Bone Metastases

Clinicopathologic Parameters

No. of Cases

Negative (n = 138)

 

PValue

(P 1, P 2

  

A* (n = 113)

B* (n = 25)

Positive

(n = 43)

 

Age (y)

     

   ≤ 60

153

94 (83.2%)

21 (84.0%)

38 (88.4%)

P 1 = 0.422

   > 60

28

19 (16.8%)

4 (16.0%)

5 (11.6%)

P 2 = 0.434

Gender

     

   Female

25

15 (13.3%)

4 (16.0%)

6 (14.0%)

P 1= 0.912

   Male

156

98 (86.7%)

21 (84.0%)

37 (86.0%)

P 2 = 0.540

HBsAg

     

   Negative

37

22 (19.5%)

5 (20.0%)

10 (23.3%)

P 1= 0.601

   Positive

144

91 (80.5%)

20 (80.0%)

33 (76.7%)

P 2 = 0.755

AFP (ng/mL)

181

    

   ≤ 20

48

28 (24.8%)

7 (28.0%)

13 (30.2%)

P 1= 0.544

   20 – 400

59

39 (34.5%)

9 (36.0%)

11 (25.6%)

P 2 = 0.648

   ≥ 400

74

46 (40.7%)

9 (36.0%)

19 (44.2%)

 

Cirrhosis

     

   Absence

45

30 (26.5%)

6 (24.0%)

9 (20.9%)

P 1= 0.469

   Presence

136

83 (73.5%)

19 (76.0%)

34 (79.1%)

P 2 = 0.768

Satellite Lesion

     

   Absence

127

94 (83.2%)

13 (52.0%)

20 (46.5%)

P 1< 0.001※

   Presence

54

19 (16.8%)

12 (48.0%)

23 (53.5%)

P 2 = 0.662

Tumor Size (cm)

181

6.04 ± 3.57

6.92 ± 3.34

7.26 ± 3.19

P 1= 0.051

P 2 = 0.676

Margins

     

   Clear

79

56 (49.6%)

10 (40.0%)

13 (30.2%)

P 1= 0.030※

   Involved

102

57 (50.4%)

15 (60.0%)

30 (69.8%)

P 2 = 0.412

Vascular invasion

     

   Absence

95

70 (61.9%)

9 (36.0%)

16 (37.2%)

P 1= 0.006※

   Presence

86

43 (38.1%)

16 (64.0%)

27 (62.8%)

P 2 = 0.921

Portal Vein Thrombosis

     

   Absence

153

97 (85.8%)

20 (80.0%)

36 (83.7%)

P 1= 0.739

   Presence

28

16 (14.2%)

5 (20.0%)

7 (16.3%)

P 2 = 0.698

Hilar lymph nodes

     

   Absence

170

109 (96.5%)

23 (92.0%)

38 (88.4%)

P 1= 0.066

   Presence

11

4 (3.5%)

2 (8.0%)

5 (11.6%)

P 2 = 0.488

UICC T stage

     

   T1

91

74 (65.5%)

7 (28.0%)

10 (23.3%)

P 1< 0.001※

   T2

38

17 (15.0%)

8 (32.0%)

13 (30.2%)

P 2 = 0.856

   T3

52

22 (19.5%)

10 (40.0%)

20 (46.5%)

 

Edmondson grade

     

   Low (I/II)

118

81 (71.7%)

15 (60.0%)

22 (51.2%)

P 1= 0.016※

   High (III/IV)

63

32 (28.3%)

10 (40.0%)

21 (48.8%)

P 2 = 0.481

CXCR4

     

   Negative

90

70 (61.9%)

11 (44.0%)

9 (20.9%)

P 1< 0.001※

   Positive

91

43 (38.1%)

14 (56.0%)

34 (79.1%)

P 2 = 0.044※

  1. * A: HCC without metastasis; B: Distal metastatic HCC without bone involvement.
  2. § P 1: Statistical analysis of HCC patients with bone metastases (n = 43) and without metastases (n = 113).
  3. P 2: Statistical analysis of distal metastatic HCC without bone involvement (n = 25) and HCC patients with bone metastases (n = 43).
  4. # Student t test.
  5. ※ Significant P value.